Burfiralimab

Names

[ Name ]:
Burfiralimab

Biological Activity

[Description]:

Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Signaling Pathways >> Anti-infection >> SARS-CoV

Research Areas >> Inflammation/Immunology

[References]

[1]. Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.